Ranked #1 by Forbes Health (2025), the app features Meal Scan photo logging, AI Coach, AI Restaurant Menu Scan, AI Voice logging, and a free Professional Connect platform for healthcare professionals
a proposed approach to this, based on our clinical experience, is overviewed below and shown in Figure 2
For semaglutide, the earliest realistic timeline for generic injectable entry: 2029: Generic manufacturers begin bioequivalence studies (2 years before the 2031 method-of-use patent expiration) 2030: ANDA submissions filed 2031-2032: FDA approvals granted, market entry Generic oral semaglutide could follow a faster timeline because Teva's Paragraph IV strategy (using a different absorption enhancer) avoids the SNAC patent entirely: 2026: Teva completes bioequivalence studies (already done as of April 2026) 2026: ANDA submission 2027: FDA approval, market entry The gap between patent expiration and market entry is why patients should not expect immediate cost relief when patents expire
Real Patient Results This is why we track body composition, not just weight
Sematrinity is indicated for type 2 diabetes and is available in two dose strengths, priced at 750 1,300 per week ( 3,000 to 5,200 per month)
